BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Breast cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for breast cancer: 793 (389 sponsors; 83 newly posted in the last 180 days, 29 stopped in the last 180 days; 40 new-entrant sponsors). Momentum score 13.8, rank 48 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 8, Phase 1 200, Phase 2 252, Phase 3 183, Phase 4 7, N/A 143.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 59 | P2 15, P3 25, NA 13, P4 2, P1 4 | 4 | 8 |
| Hoffmann-La Roche | 23 | P4 1, P3 11, NA 2, P2 9 | 2 | 2 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 23 | P1 10, P2 4, P3 9 | 4 | 5 |
| Eli Lilly and Company LLY | 25 | P1 12, P3 8, P2 5 | 1 | 2 |
| Jiangsu HengRui Medicine Co., Ltd. | 12 | P3 8, P2 3, P1 1 | 2 | 2 |
| Merck Sharp & Dohme LLC MRK | 10 | P3 7, P2 3 | 0 | 1 |
| Pfizer PFE | 23 | P1 3, NA 4, P3 5, P2 10, P4 1 | 3 | 6 |
| Gilead Sciences GILD | 9 | P3 5, P2 4 | 0 | 3 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | 7 | P3 5, P2 2 | 1 | 3 |
| Novartis Pharmaceuticals NVS | 34 | P1 10, P2 7, NA 12, P3 4, P4 1 | 7 | 10 |
| Shanghai Henlius Biotech | 9 | P2 4, P3 4, P1 1 | 2 | 3 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 8 | P2 3, P1 1, P3 4 | 1 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 6 | P3 4, P1 1, P2 1 | 0 | 0 |
| Shanghai JMT-Bio Inc. | 5 | P3 4, P2 1 | 0 | 1 |
| Daiichi Sankyo | 9 | NA 2, P3 3, P2 3, P1 1 | 2 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 7 | P3 3, P2 4 | 1 | 3 |
| Shandong Suncadia Medicine Co., Ltd. | 7 | P2 3, P3 3, P1 1 | 1 | 1 |
| Qilu Pharmaceutical Co., Ltd. | 6 | P1 1, P2 2, P3 3 | 1 | 2 |
| Genentech, Inc. | 6 | P1 3, P3 2, P2 1 | 1 | 1 |
| Seagen, a wholly owned subsidiary of Pfizer | 6 | P2 2, P1 2, P3 2 | 0 | 0 |
| Olema Oncology, Inc. OLMA | 5 | P3 2, P1 3 | 0 | 0 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | 4 | P2 2, P3 2 | 1 | 0 |
| DualityBio Inc. | 4 | P2 2, P3 2 | 0 | 0 |
| Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 4 | P3 2, P2 2 | 0 | 0 |
| Shanghai Pharmaceuticals Holding Co., Ltd | 3 | P3 2, P2 1 | 0 | 2 |
Recently stopped trials
- NCT06107894 NeogenTC - terminated: It is due to difficulties in enrolling participants. TIL Therapy for Patients With Advanced Solid Tumors
- NCT06171789 Genmab - terminated: Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation PRO1107 in Patients With Advanced Solid Tumors
- NCT06125522 Pfizer - terminated: Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to saf TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Adva
- NCT05573555 Pfizer - terminated: Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to sa TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Adva
- NCT06568692 Processa Pharmaceuticals - terminated: Business Reason A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- NCT01113970 Alaunos Therapeutics - terminated: Sponsor business decision: enrollment closed after the Phase 1 dose escalation, before an MTD was reached. The Phase 2 portion was not condu Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
- NCT05384119 Tvardi Therapeutics, Incorporated - terminated: The study was terminated prior to Phase 2 due to slow accrual. Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Brea
- NCT06714617 SystImmune Inc. - terminated: The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the i Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
- NCT04638751 Persephone Biosciences - suspended: Currently no funding to continue study. ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
- NCT06560385 GenieBiome Limited - terminated: No enough subjects within the recruitment period Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula
- NCT04191135 Merck Sharp & Dohme LLC - terminated: Business Reasons Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy
- NCT04982848 Pfizer - withdrawn: Withdrawal of the marketing authorization for the breast cancer indication of Talzenna® in Korea, not related to safety concerns or any regu Korea Post Marketing Surveillance (PMS) Study of Talzenna®
- NCT04251533 Novartis Pharmaceuticals - terminated: The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not drive Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a
- NCT07214662 Genentech, Inc. - terminated: The trial was terminated due to sponsor decision. A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire
- NCT05827614 Boundless Bio, Inc. - terminated: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safe Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P3 | InventisBio Co., Ltd | NCT06954961 A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | Breast Cancer | recruiting | 640 |
| 2026-11-30 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06968585 A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab | HER2-positive Breast Cancer | active not recruiting | 365 |
| 2026-12 est. | P1/P2 | Phoenix Molecular Designs | NCT04115306 Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | Metastatic Breast Cancer | active not recruiting | 61 |
| 2026-12 est. | P1/P2 | Sapience Therapeutics | NCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Glioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brain | active not recruiting | 125 |
| 2026-12 est. | P3 | Gilead Sciences GILD | NCT04639986 Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | Metastatic Breast Cancer | active not recruiting | 331 |
| 2026-12 est. | P2 | Ambrx, Inc. | NCT04829604 ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | HER2 Positive Metastatic Breast Cancer | active not recruiting | 72 |
| 2026-12 est. | P1/P2 | Stemline Therapeutics, Inc. | NCT05386108 Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous Sy | recruiting | 73 |
| 2026-12 est. | P1/P2 | SynDevRx, Inc. | NCT05455619 Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer | HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer | recruiting | 52 |
| 2026-12 est. | P1/P2 | Monte Rosa Therapeutics, Inc GLUE | NCT05546268 Study of Oral MRT-2359 in Selected Cancer Patients | NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC | active not recruiting | 174 |
| 2026-12 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05780567 Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Canc | Breast Cancer | active not recruiting | 1946 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06042894 A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer | Breast Cancer | recruiting | 58 |
| 2026-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06202261 A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies | recruiting | 154 |
| 2026-12 est. | P1/P2 | 858 Therapeutics, Inc. | NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovar | recruiting | 120 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06471205 A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer | Triple-negative Breast Cancer | recruiting | 52 |
| 2026-12 est. | P3 | Akeso | NCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | Triple-Negative Breast Cancer (TNBC) | recruiting | 416 |
| 2026-12 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06974929 A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer | Breast Cancer | recruiting | 80 |
| 2026-12-01 est. | P2/P3 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05860465 Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer | Locally Advanced or Metastatic Breast Cancer | recruiting | 254 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-16 est. | P3 | Shanghai JMT-Bio Inc. | NCT06747338 A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | Early or Locally Advanced HER2-positive Breast Cancer | active not recruiting | 520 |
| 2026-12-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | NCT06062810 Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms | Breast Cancer | active not recruiting | 600 |
| 2026-12-27 est. | P1/P2 | Stemline Therapeutics, Inc. | NCT05563220 Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | Breast Cancer; Metastatic Breast Cancer | active not recruiting | 435 |
| 2026-12-28 est. | P2 | GlaxoSmithKline | NCT04641247 A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Ovarian Neoplasms; Breast Neoplasms | recruiting | 37 |
| 2026-12-30 est. | P2 | Akeso | NCT05227664 A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | Metastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Cancer | active not recruiting | 120 |
| 2026-12-30 est. | P3 | Pfizer PFE | NCT05909397 Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | Breast Cancer | active not recruiting | 59 |
| 2026-12-30 est. | P2 | Shanghai Henlius Biotech | NCT07459738 A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Ca | Hormone Receptor Positive HER-2 Negative Breast Cancer | not yet recruiting | 60 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P1/P2 | BicycleTx Limited | NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer | active not recruiting | 288 |
| 2026-12-31 est. | P2 | Pfizer PFE | NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | active not recruiting | 157 |
| 2026-12-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05424835 A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuz | active not recruiting | 381 |
| 2026-12-31 est. | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05872347 Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. | Breast Cancer Brain Metastases | recruiting | 52 |
| 2026-12-31 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | Metastatic Breast Cancer | recruiting | 376 |
| 2026-12-31 est. | P2 | Rhizen Pharmaceuticals SA | NCT06189209 Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | Triple Negative Breast Cancer (TNBC) | recruiting | 40 |
| 2026-12-31 est. | P2 | Abscint NV/SA | NCT06369831 HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011 | Metastatic Breast Cancer; Metastatic Solid Cancer | recruiting | 60 |
| 2026-12-31 est. | P2 | Jazz Pharmaceuticals JAZZ | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endome | recruiting | 200 |
| 2027-01 est. | P1/P2 | BicycleTx Limited | NCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negative | active not recruiting | 329 |
| 2027-01 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06561607 A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer | Breast Cancer | active not recruiting | 542 |
| 2027-01 est. | P1/P2 | Marengo Therapeutics, Inc. | NCT06827613 A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govit | Triple Negative Locally Advanced Non-resectable Breast Cancer; HR+, HER2-, Advanced Breast Cancer | recruiting | 50 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-01-09 est. | P3 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | NCT07673029 A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | HER2-positive Breast Cancer | recruiting | 228 |
| 2027-01-15 est. | P2 | Biostar Pharma, Inc. | NCT06764940 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | HER2-negative Breast Cancer Patients With Brain Metastases | recruiting | 120 |
| 2027-01-28 est. | P3 | Novartis Pharmaceuticals NVS | NCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatm | Breast Cancer | active not recruiting | 210 |
| 2027-01-29 est. | P2 | Novartis Pharmaceuticals NVS | NCT04544189 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women Wit | Breast Neoplasms | active not recruiting | 69 |
| 2027-01-30 est. | P3 | Tolmar Inc. | NCT04906395 Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Breast Cancer | active not recruiting | 250 |
| 2027-02 est. | P1/P2 | Day One Biopharmaceuticals, Inc. | NCT05377996 A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | Triple Negative Breast Cancer; Breast Cancer; Endometrial Cancer; Ovarian Cancer; Fallopian Tube Can | recruiting | 360 |
| 2027-02 est. | P3 | Gilead Sciences GILD | NCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Ad | Triple Negative Breast Cancer; PD-L1 Positive | active not recruiting | 443 |
| 2027-02 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT07173556 A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer | Advanced Breast Cancer | not yet recruiting | 96 |
| 2027-02-10 est. | P2 | AstraZeneca AZN | NCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | active not recruiting | 127 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07486089 Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) | Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer; Triple-Negative Breast | recruiting | 60 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-13 est. | P3 | Hoffmann-La Roche | NCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negati | Breast Cancer | recruiting | 420 |
| 2026-11 est. | P3 | EirGenix, Inc. | NCT06884254 Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negat | Early Breast Cancer | withdrawn | |
| 2026-11 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid Tumors | NSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumors | recruiting | 200 |
| 2026-11 est. | P2 | Atossa Therapeutics, Inc. ATOS | NCT05607004 (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer; HER2-negative Br | active not recruiting | 87 |
| 2026-11 est. | P2 | Stemline Therapeutics, Inc. | NCT05596409 ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | Metastatic Breast Cancer | active not recruiting | 61 |
| 2026-10-31 est. | P3 | AstraZeneca AZN | NCT06635447 Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients | Breast Cancer | active not recruiting | 293 |
| 2026-10-31 est. | P1/P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06222879 Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer | Breast Cancer | unknown | 350 |
| 2026-10-31 est. | P3 | Olema Oncology, Inc. OLMA | NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Neg | active not recruiting | 510 |
| 2026-10-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04842617 Phase III Study :SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage | active not recruiting | 5274 |
| 2026-10-30 est. | P3 | Natureceuticals Sdn Bhd | NCT07669467 Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer | Fatigue Related to Cancer Treatment; Breast Cancer | recruiting | 250 |
| 2026-10-30 est. | P1/P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06679036 A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients | Advanced Unresectable or Metastatic Breast Cancer | recruiting | 300 |
| 2026-10-30 est. | P3 | Laekna Limited | NCT04851613 Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer | Breast Cancer | active not recruiting | 256 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-15 | P2 | Hoffmann-La Roche | NCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced | Breast Cancer | completed | 83 |
| 2026-10-13 est. | P3 | Shanghai JMT-Bio Inc. | NCT06846437 JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | recruiting | 228 |
| 2026-10-11 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT07083505 A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer | Advanced Breast Cancer | not yet recruiting | 60 |
| 2026-10-06 | P1/P2 | Pfizer PFE | NCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-St | Breast Cancer | terminated | 20 |
| 2026-10-01 est. | P2 | RemeGen Co., Ltd. | NCT06642545 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer | Breast Cancer | recruiting | 40 |
| 2026-10 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06929325 Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibi | HR+/HER2- Advanced/Metastatic Breast Cancer | not yet recruiting | 312 |
| 2026-10 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06316531 A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | HER2-positive Breast Cancer | active not recruiting | 274 |
| 2026-09-10 | P1/P2 | Pfizer PFE | NCT06125522 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-S | Breast Cancer | terminated | 11 |
| 2026-09-01 est. | P1/P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07169994 A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | Advanced Solid Tumors; Breast Cancer; Non Small Cell Lung Cancer | recruiting | 414 |
| 2026-09 est. | P1/P2 | TYK Medicines, Inc | NCT06950086 Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors | HR-positive, HER2-negative Advanced Breast Cancer | recruiting | 180 |
| 2026-08-31 est. | P2 | Nantong Bencao Quadriga Medical Technology Co. Ltd. | NCT06810804 A Phase IIa Study to Evaluate NBQ72S | Breast Cancer | recruiting | 10 |
| 2026-08-18 est. | P3 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | NCT06519370 FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | Triple Negative Breast Cancer | active not recruiting | 350 |
| 2026-08-12 | P3 | DualityBio Inc. | NCT06018337 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Metastatic Breast Cancer | active not recruiting | 541 |
| 2026-08 est. | P2 | Tasly Biopharmaceuticals Co., Ltd. | NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervic | not yet recruiting | 120 |
| 2026-08 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06343948 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Canc | HR+HER2- Breast Cancer | active not recruiting | 383 |
| 2026-08 est. | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT05490472 JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Solid Tumors; ER+ Breast Cancer; Triple Negative Breast Cancer, TNBC; ARID1A Gene Mutation; Small Ce | recruiting | 102 |
| 2026-08 est. | P1/P2 | Treadwell Therapeutics, Inc | NCT05251714 CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | Advanced Solid Tumor; Breast Cancer | active not recruiting | 44 |
| 2026-08 est. | P1/P2 | AtlasMedx, Incorporated | NCT04503265 A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Advanced Malignant Neoplasm; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency; Pro | recruiting | 122 |
| 2026-07-31 | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05445908 SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer | Triple-negative Breast Cancer and HR+/HER2- BC | completed | 184 |
| 2026-07-29 | P2 | Processa Pharmaceuticals PCSA | NCT06568692 A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer | terminated | 20 |
| 2026-07-28 est. | P1/P2 | Lantern Pharma Inc. LTRN | NCT05933265 Study of LP-184 in Patients With Advanced Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Panc | active not recruiting | 64 |
| 2026-07-15 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT07116824 HB1801 Combined Treatment of HER2-positive Breast Cancer | HER2-positive Breast Cancer | not yet recruiting | 80 |
| 2026-07-15 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06057610 A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer | HER2-PositiveRecurrent or Metastatic Breast Cancer | active not recruiting | 868 |
| 2026-07-01 est. | P1/P2 | Scancell Ltd SCNLD | NCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer | Triple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamous | recruiting | 168 |
| 2026-07 est. | P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06492005 A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer | Triple-Negative Breast Cancer | recruiting | 160 |
| 2026-06-30 est. | P3 | Kexing Biopharm Co., Ltd. | NCT06711523 Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy | Neutropenia, Chemotherapy-Induced Febrile; Breast Neoplasm Female | active not recruiting | 250 |
| 2026-06-30 est. | P3 | Celcuity Inc CELC | NCT05501886 Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer ( | Breast Cancer | active not recruiting | 701 |
| 2026-06-26 | P3 | AstraZeneca AZN | NCT04711252 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Receiv | ER-Positive HER2-Negative Breast Cancer | active not recruiting | 1371 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06702618 Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer | Breast Cancer | active not recruiting | 33 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06452706 The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Breast Cancer | recruiting | 42 |
| 2026-06 est. | P2 | RemeGen Co., Ltd. | NCT06178159 DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer | Breast Cancer | recruiting | 40 |
| 2026-06 est. | P1/P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06167694 Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer | Unresectable or Metastatic Breast Cancer | recruiting | 146 |
| 2026-06 est. | P1/P2 | Volastra Therapeutics, Inc. | NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Advanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancer | recruiting | 200 |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
| 2026-05-31 est. | P2/P3 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05744687 Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer | Locally Advanced or Metastatic Breast Cancer | recruiting | 374 |
| 2026-05-26 est. | P2 | JenKem Technology Co., Ltd. | NCT06586866 JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases | Triple Negative Breast Cancer (TNBC); Brain Metastasases | unknown | 25 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "breast cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.